Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Dernoscheg Marie-Therese |
** = Publikationen gelistet in SCI/SSCI/Pubmed
2023
Kurzbericht/Letter
** Buchacher, L; Richtig, G; Dernoscheg, M; Richtig, E; Koch, L
Permanent dose reduction due to adverse reactions does not decrease efficacy of BRAF/MEK inhibition in metastatic melanoma.
J Eur Acad Dermatol Venereol. 2023; 37(5):e605-e607
Doi: 10.1111/jdv.18871
Web of Science
PubMed
FullText
FullText_MUG
** Grossschaedl, K; Vallant, C; Dernoscheg, MT; Richtig, M; Öllinger, A; Balakirski, G; Wilsmann-Theis, D; Nguyen, VA; Weinlich, G; Tsiogka, A; Koelblinger, P; Scheffel, J; Richtig, E; Richtig, G
Usage and benefit of the Internet as a source of information on disease and therapy in dermatology.
J Dtsch Dermatol Ges. 2023; 21(11): 1383-1386.
Doi: 10.1111/ddg.15199
Web of Science
PubMed
FullText
FullText_MUG
** Grossschaedl, K; Vallant, C; Dernoscheg, MT; Richtig, M; Öllinger, A; Balakirski, G; Wilsmann-Theis, D; Nguyen, VA; Weinlich, G; Tsiogka, A; Koelblinger, P; Scheffel, J; Richtig, E; Richtig, G
[Verwendung und Nutzen des Internets als Informationsquelle für Erkrankungen und Therapien in der Dermatologie: Usage and benefit of the Internet as a source of information on disease and therapy in dermatology].
J Dtsch Dermatol Ges. 2023; 21(11): 1383-1386.
Doi: 10.1111/ddg.15199_g
PubMed
FullText
FullText_MUG
2022
Abstract (Zeitschrift)
** Debus, D; Alter, M; Dernoscheg, MT; Rohrer, P; Koch, L; Nguyen, VA; Terheyden, P
Retrospective Single Case Reports on the Treatment of Advanced BRAFV600-mutated Malignant Melanoma with Encorafenib plus Binimetinib (REMINISCENCE)
ONCOL RES TREAT. 2022; 45(SUPPL 3):237-237.NOV 13-16, 2022; Berlin, GERMANY.
[Poster]
Web of Science
** Grote, C; Debus, D; Bluhm, L; Koch, L; Alter, M; Dernoscheg, M; Nepel, C; Rohrer, P; Kahler, K; Tuting, T; Gengen-Bacher, L; Nguyen, V; Terheyden, P
Retrospective Survey of Individual Case Reports on Treatment Situations in Patients with locally advanced or metastatic, BRAFV600-mutated Melanoma with Encorafenib and Binimetinib (REMINISCENCE).
J DTSCH DERMATOL GES. 2022; 20: 30-30.-ADO 2022; SEP 14-17, 2020; Hannover.
[Poster]
Web of Science
2021
Originalarbeit (Zeitschrift)
** Koelblinger, P; Hoellwerth, M; Dernoscheg, MT; Koch, L; Richtig, E; Wanner, M; Nguyen, VA; Ostermann, H; Bauer, JW; Laimer, M
Adjuvant anti-PD-1 antibody treatment in stage III/IV melanoma: real-world experience and health economic considerations
J DTSCH DERMATOL GES. 2021;
Doi: 10.1111/ddg.14511
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG